The epigenome of the malaria parasite, Plasmodium falciparum, is associated with control of various essential processes in the parasite including control of proliferation of asexual development as well as sexual differentiation. The unusual nature of the epigenome has prompted investigations of the potential to target epigenetic modulators with novel chemotypes. Here, we explored the diversity associated with a library of 95 compounds, active against various epigenetic modifiers within cancerous cells, for activity against multiple stages of P. falciparum development. We show that P. falciparum is differentially susceptible to epigenetic perturbation during asexual and sexual development, with early stage gametocytes particularly sensitive to epi-drugs targeting both histone and non-histone epigenetic modifiers. Moreover, 4 compounds targeting histone acetylation and methylation, show potent multistage activity against asexual parasites, early and late stage gametocytes, with transmission-blocking potential. Overall, these results warrant further examination of the potential antimalarial properties of these hit compounds.
Background
The almost inevitable nature of drug resistance development by malaria parasites enforces continued exploration of novel classes of antimalarial drugs. To contribute to global malaria elimination strategies (1, 2) , such compounds would need to target multiple life cycle stages including the rapidly dividing asexual parasites for chemotherapies, as well as terminally differentiated sexual gametocytes for transmission-blocking activity. Importantly, to prolong resistance development, new chemical matter targeting novel biological activities in the parasite is needed.
In oncology research, epigenetic therapeutics ('epi-drugs') that inhibit epigenetic modulators evidently hold great promise as targets for anticancer therapies (3) . The result is an epigenetic de-regulation with antitumor activity, due to targeting histone modifying enzymes and DNA methyltransferases, or facilitating reader interference by inhibiting or activating epigenetic processes. This results in particularly histone posttranslational modifications (PTMs) and disruption of transcriptional processes, chromatin structure maintenance and DNA repair (4, 5) . Various anticancer epi-drugs have been approved for clinical use, including Azacitidine, Decitabine, Vorinostat and Romidepsin (6) .
Plasmodium falciparum relies heavily on epigenetic mechanisms to drive both asexual proliferation and sexual differentiation (reviewed in (7) (8) (9) (10) (11) ). The parasite's genome encodes a unique complement of histone modifying enzymes including histone deacetylases (HDACs), histone acetyltransferases (HATs), histone methyltransferases (HMTs, including lysine HKMT), protein arginine methyltransferases (PRMTs), and histone demethylases (HDMs) (11) in addition to other non-histone epigenetic modifiers. As a result, inhibitors of particularly histone modifying enzymes have been investigated as novel chemotypes in antimalarial drug discovery efforts (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) .
Selective anticancer epi-drugs have been investigated for their activity against P.
falciparum asexual parasites and to a lesser extent, against gametocyte stages. These compounds disturb the parasite's gene expression, ultimately leading to cell death (20) (21) (22) . HDACs are seen as particularly promising drug targets due to resultant hyperacetylation (on various histone sites) upon disruption of these activities, with
HDACi (HDAC inhibitors) receiving the vast majority of interest. This includes wellknown hydroxymate-based inhibitors like SAHA (suberoylanilide hydroxamic acid, Vorinostat and its derivates) and TSA (Trichostatin A) as well as cyclic tetrapeptides like apicidin, which have shown selective inhibition against asexual P. falciparum stages (17, (22) (23) (24) (25) (26) and gametocytes (17, 26) . SAHA additionally retained activity in clinical isolates of both P. falciparum and P. vivax (27) . These data have led to larger screens for diverse and selective inhibitors of HDACs (14, (28) (29) (30) . In P. falciparum, histone lysine methyltransferases (HKMTs) are involved in both transcriptional activation (through H3K4me marking) and repression (e.g. H3K9me marks), and are also hypothesised to be promising drug targets (16) , with BIX01294 (as model HKMT inhibitor, HKMTi) successfully inhibiting asexual P. falciparum proliferation and gametocyte viability (15, 16) . The diaminoquinazoline chemotype has shown to be particularly effective HKMTi against asexual P. falciparum parasites, with diversity set screens resulting in selective inhibitors identified (15, 16, 19) . Although these data support the notion that epigenetic modulators could be drug targets in parasite development as well as differentiation, some chemotypes show overt toxicity, poor selectivity and sometimes poor pharmacokinetics (31) . Diverse chemotypes targeting various epigenetic modulators should therefore be explored.
In this study, a library of anticancer compounds (Cayman Epigenetics Screening 
Results

Comparative profiling of the Cayman Epigenetics library for inhibition activity against P. falciparum parasites
All 95 compounds in the Cayman Epigenetics library were profiled for in vitro activity against asexual and sexual P. falciparum parasites in a dual-concentration screen (1 and 5 µM, Figure 1A , supplemental figure 1, supplementary file 1). This included stage-specific evaluation of the compounds against early (>85% stage II/III) and late stage (>95% stage IV/V) gametocytes. The majority of the compounds (76% against asexual parasites, early (69%) and late (82%) stage gametocytes) showed no/minimal activity. Although similar hit rates and compound identities were observed between asexual parasites and early stage gametocytes (24 and 30% of compounds, respectively, active against these stages at >50% inhibition, Pearson correlation r 2 of 0.5), the distribution of compounds displaying moderate activity against early stage gametocytes were almost double that against asexual parasites (18 vs. 10%). Overall, the compounds were the least active against late stage gametocytes (18% hit rate).
Additionally, the nature of the compounds active against asexual parasites and late gametocytes (and between those active against early and late stage gametocytes) showed poor correlation (r 2 of 0.3 and 0.2, respectively), indicating some stagespecificity in the distribution of the compounds active against each stage.
Hierarchical clustering of the compounds based on Euclidean distances further revealed this stage-specific distribution ( Figure 1A) . A subset of 17 compounds (including well known compounds like TSA, SAHA, BIX01294 and HC Toxin), display activity against all life cycle stages tested, marking these compounds as multistage inhibitors. However, 4 compounds (PCI34051, C646, 3-amino benzamide and sirtinol)
show late stage gametocyte preference with an additional 10 compounds clustered due to increased activity towards early stage gametocytes.
The multistage activity of the 95 compounds was stratified based on the inhibitor classes descriptors for these compounds ( Figure 1B ). As expected, the majority of the active compounds are classified as HDACi and HKMTi, and compounds from these classes target all life cycle stages ( Figure 1C ). Interestingly, compounds classified in the library as potential DNDM, DNMT, PRMT and HAT inhibitors were within the 'hit' pool. However, inhibitors targeting bromodomain proteins, hydroxylation, phosphorylation, and demethylation activities (both histone demethylase and lysinespecific demethylase) were not particularly active (<50% inhibition). Compounds with >50% inhibition (at 5 μM) against all three parasite stages included mostly HDACi 
Antiproliferative activity against asexual parasites
Of the hits described above, 19 compounds were selected for IC50 determination against both drug sensitive (3D7) and resistant (K1 and W2) strains of P. falciparum parasites ( Figure 2A , Table 1 ). Collectively, IC50 values ranged between 7 nM to 6 μM for all the parasite strains evaluated. The resistance indices (RI; ratio of the IC50 value of the resistant strain to the sensitive strain, i.e. K1/3D7 and W2/3D7) averaged at 1.12, indicating limited cross-resistance to the K1 and W2 P. falciparum parasite strains ( Table 1) . Five compounds were extremely potent at <100 nM against all parasite strains, with the most active compounds (3-Deazaneplanocin A, BIX01294, UNC0638) classified as HKMTi, followed by two HDACi, HC Toxin and TSA. TSA, BIX01294 and SAHA showed similar IC50 values to those found in previous reports (16, 17, 22) . 3-Deazaneplanocin A could, however, consistently not cause complete parasite clearance, even up to 100 μM or prolonged exposure (up to 96 h tested). All of the compounds with activity below 500 nM belong to the HDACi class, emphasizing the importance of this activity for asexual proliferation of P. falciparum.
Since the compounds in the library were included based on evidence of activity against mammalian lines, their selective toxicity towards P. falciparum parasites was determined ( Table 1 ). All of the most potent compounds, except for HC Toxin, showed preference towards P. falciparum parasites, with particularly BIX01294 and UNC0638
highly selective towards the parasite with SI>300, supporting that HKMT activity is essentially important to malaria parasite proliferation. CAY10603 and suberohydroxamic acid (HDACi) and ellagic acid (a PRMTi), were also 10-fold more active against the parasite than mammalian cells with SI values >10. These compounds therefore result in a base set of chemical entities that can be explored in medicinal chemistry programs, with selective inhibition towards malaria parasites.
Gametocytocidal and gametocidal activity
Selected compounds were evaluated for their activity on both early and late stage gametocytes, with 8 compounds showing activity at <5 μM on gametocytes ( Figure 3 (17)).
CAY10603, Chaetocin and Oxflamfatin was able to reduce the normal ~3:1 ratio of female:male mature gametocytes to equal proportions ( Figure 3B ). In addition, Chaetocin and sirtinol, and to a lesser extent CAY10603, affected the functional viability of male gametocytes to exflagellate (>60% inhibition) ( Figure 3C ). With these also affecting female gametocytes, it points to shared biological activities being targeted rather than sex-specific processes.
HDACi and HKMTi as multistage targeting epi-drugs
As the HDACi and HKMTi showed the most extensive activity against multiple P.
falciparum parasite stages, the potential for structure activity relationships between these two inhibitor classes were explored ( Figure 4 ). Although the majority (>80%) of the compounds were not structurally related, even though they did show activity in the primary screen against multiple stages, a core hydroxamate-based scaffold could be identified for 5 HDACi, which showed ˃80% structural similarity, including Pyroxamide, SAHA, 4-iodo-SAHA, CAY10433 and Pimelic Diphenylamide 106. Conversely, 4
HKMTi showed ˃80% structural similarity as 4-quinazolinamine-based structures, including BIX01294, UNC0638, UNC0224 and UNC0321. A few other structurally similar pairs were also identified, including CAY10398 and M 344 (both HDACi) that has multistage activity and only differs with a single backbone carbon. These compounds show promise as chemical starting points for antimalarial optimisation as they have unique chemical scaffolds compared to most compounds and have an altered molecular target.
Discussion
The P. falciparum parasite's epigenetic regulatory machinery has previously been shown to be a valuable drug target given the importance of gene expression for parasite development, but remains to be exploited in full (15, 16, 22, 23, (32) (33) (34) (35) . In this study, various compounds, known to target the epigenetic modulators, were Gemcitabine was also shown to have stage-specificity for asexual stages, suggesting possible and antagonistic involvement of DNA methylation-linked chromatin condensation in these stages of development (36) . PRMTi were moderately active against asexual and early gametocyte stages. This includes Ellagic Acid, which was previously indicated as potent against asexual parasites (37) . Although antioxidant pleiotropic effects of this compound cannot be ignored, the multistage activity reported here suggests a possible role of arginine methylation during these stages (38) , but not in mature gametocytes.
Histone-associated epigenetic regulators remain overrepresented as targets, both due
to the composition of the library screened, but also due to the known importance of histone acetylation and methylation to parasite survival (21, 39) . However, HDACs and HKMTs remain the activities targeted the most frequently; a single HATi was identified with multistage activity (C 646, specific competitive inhibitor of human p300 HAT). Hydroxamate-based HDACi and 4-quinazolinamine-based HKMTi remained the most potent chemical scaffolds that target Plasmodium parasite development at the symptomatic asexual and transmissible gametocyte forms. Hydroxamate-based HDACi were previously shown to have potent antiplasmodial activity with limited cytotoxicity, and this class contains some clinically approved compounds which have been attempted in drug repurposing studies (22, 24, (40) (41) (42) (43) . These compounds lead to DNA hyper-acetylation, resulting in the de-regulation of transcription and ultimately cell cycle arrest and cell death (25, 26, 44, 45) . Some HDACi were also completely pan-inactive, thereby suggesting that the parasite relies on a specific set of HDACs to regulate its chromosomal condensation via acetylation (reviewed in (46) ). The hit
HDACi selected in this study display unique chemical scaffolds and showed activity against all stages, although not at equipotent levels (CAY10603, ITF 2357 and Oxamflatin), with potenty increased against asexual parasites and early stage gametocytes. Comparatively, HKMTi overall has the best potency and selectivity with additional activity retained against transmissible stages, similar to previous reports on 4-Quinazolinamine-based HKMTi (15, 16) . Selective inhibition of HKMT activity can either lead to an increase or decrease in transcription, depending on the position and degree of methylation and ultimately contributes to transcriptional de-regulation and cell death (16) . For instance, the HKMTi, 3-Deazaneplanocin A, selectively inhibits H3K27me3 and H4K20me3, and reactivates silenced developmental genes in cancer cells that are not silenced by DNA methylation (47) .
The stage-specific inhibition profiles observed for the wide variety of epi-drug inhibitor classes support the findings that the parasite makes use of altered epigenetic regulatory mechanisms to differentiate itself during asexual proliferation and sexual differentiation (7, 48, 49) . Selective Plasmodium inhibition was only shown for 6 compounds of the series, which suggests that the epigenetic modulators targeted by these compounds (HKMT, HDAC and PRMT) show diversity between the parasite and human homologues, as previously shown by the unique set of Plasmodium-specific epigenetic factors that differs vastly from those in its mammalian host (39) . The primary evaluation of the activity of epi-drugs against the multiple life cycle stages indicated that early stage gametocytes were particularly susceptible to epi-drug inhibition, supported by reports of a unique epigenetic repertoire associated with these stages, where the switch between asexual and sexual stages was accompanied by dynamic histone PTM landscape alterations (7) . The differentiation between the compounds active against the different life cycle stages correlates with unique and stage-specific histone PTM dynamics during the parasite's life cycle, with clear peaks abundances for some epigenetic marks associated with particular life cycle stages (7, 48, 49) and highlights the importance of these activities to parasite development.
Collectively, the data implies that the epigenetic modulators affected are essential for parasite development throughout its asexual and sexual life cycle. Our study reveals that certain chemical scaffolds shared between multistage active compounds hold potential as chemical starting points for further development of derivatives with increased potency, selectivity, or improved physico-chemical properties.
Materials & Methods
Asexual P. falciparum parasite cultivation and antiproliferative assays P. falciparum parasites were maintained at 37˚C in human erythrocytes suspended in complete culture medium and ring-stage synchronised as described (50) . SYBR 
Parasite lactate dehydrogenase assay to determine inhibition against the early and late stage P. falciparum gametocytes
Gametocytes were induced from asexual P. falciparum NF54 parasites as described before (50) . The parasite lactate dehydrogenase (pLDH) assay was performed as previously described (50, 52, 53) . Early and late stage P. falciparum gametocyte cultures (2% haematocrit, 5% gametocytaemia) were treated with compounds at 1 and Assay performances were evaluated with average %CV at 4.54 and Z-factors at >0.5.
Data analysis
Chemi-informatics evaluation of compound activities including structure-activity landscape analysis was performed with Osiris DataWarrier v4.7.2
Gamete formation assays.
Male and female gametocytes were detected visually with Giemsa stain after 48 h drug pressure, by counting at least 1000 cells. The male exflagellation inhibition assay Movement was recorded by video microscopy using a Carl Zeiss NT 6V/10W Stab microscope, fitted with a MicroCapture camera at 10X magnification and then quantified by a semi-automated method, a modification of the method described by (54) . A series of 15 videos of 8-10 seconds each were captured at random locations between minute 15 and 22.5 after incubation. Each video was analysed using Icy bioimage analysis software in order to quantify the number of exflagellating centres.
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